Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Alzheimer's drug trial aims to slow memory loss

NCT ID NCT07599670

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen May 24, 2026 · Last updated May 24, 2026

Summary

This study tests an experimental drug called ABBV-1758 in about 210 adults with early Alzheimer's disease. The drug is given as an infusion or injection every 4 weeks for 24 weeks. Researchers will check for side effects and measure changes in brain amyloid plaques using PET scans. The goal is to see if the drug is safe and can slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.